secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K
Filed at:   2026-06-04T20:01:13+00:00
Accession:  0001104659-26-070494
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Aclaris shareholders elect directors, approve executive pay at 2026 annual meeting
--------------------------------------------------------------------------------

- 80.55% of shares voted; 112,499,671 of 139,663,680 outstanding shares represented.
- Elected Anand Mehra and Maxine Gowen as directors with 83.1M and 84.2M votes for, respectively.
- Advisory vote on named executive officer compensation approved: 83.4M for, 9.7M against.
- Ratification of PricewaterhouseCoopers as auditor passed with 112.3M votes for.
- Broker non-votes of 19.4M on proposals 1 and 2; no broker non-votes on auditor ratification.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000110465926070494/0001104659-26-070494-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000110465926070494/acrs-20260604x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-070494

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer